Tissue plasminogen activator for acute ischaemic stroke

Julia J Batmanian, Meeyin Lam, Caitlin Matthews, Andrew Finckh, Martin Duffy, Robert Wright, Bruce J Brew and Romesh Markus
Med J Aust 2008; 188 (8): . || doi: 10.5694/j.1326-5377.2008.tb01732.x
Published online: 21 April 2008

In reply: We welcome the opportunity to respond to issues raised by Hurley and Toncich. Australian, United States and European stroke guidelines based on level 1, grade A evidence recommend intravenous recombinant tissue plasminogen activator (IV-rtPA) for patients with acute ischaemic stroke (AIS) who meet specific inclusion criteria and present within 3 hours of AIS onset.1,2 Recombinant tPA is approved for this indication by the Therapeutic Goods Administration.

  • Julia J Batmanian1
  • Meeyin Lam1
  • Caitlin Matthews1
  • Andrew Finckh1
  • Martin Duffy1
  • Robert Wright1
  • Bruce J Brew2,1
  • Romesh Markus1,2

  • 1 St Vincent’s Hospital, Sydney, NSW.
  • 2 University of New South Wales, Sydney, NSW.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.